An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits.

JR, Wetterau; RE, Gregg; TW, Harrity; C, Arbeeny; M, Cap; F, Connolly; CH, Chu; RJ, George; DA, Gordon; H, Jamil; KG, Jolibois; LK, Kunselman; SJ, Lan; TJ, Maccagnan; B, Ricci; M, Yan; D, Young; Y, Chen; OM, Fryszman; JV, Logan; CL, Musial; MA, Poss; JA, Robl; LM, Simpkins; WA, Slusarchyk; R, Sulsky; P, Taunk; DR, Magnin; JA, Tino; RM, Lawrence; JK Jr, Dickson; SA, Biller

doi:10.1126/science.282.5389.751

Public

An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits.

Shared by NobleBlocks on Oct 1, 1998 • 12:00 AM UTC

Authors:

Wetterau JR

Gregg RE

Harrity TW

Abstract

Patients with abetalipoproteinemia, a disease caused by defects in the microsomal triglyceride transfer protein (MTP), do not produce apolipoprotein B-containing lipoproteins. It was hypothesized that small molecule inhibitors of MTP would prevent the assembly and secretion of these atherogenic lipo...

Discussions